



12 Nov. 2025

SYN-TECH CHEM.& PHARM.CO.,LTD

Industry Forum

Chen-Ming, Hsiao Chairman



生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777



Safe Harbor Notice

- ★ **In these presentations and discussions, there are certain forward-looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.**
- ★ **We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.**



CONTENTS

Company Brief Introduction

Brief overall
Main Products
DMF/MF Registration Status
Official and Customer Audit Records

Business and Financial Statements

Performance for operation

Strategy in the Future Development & forward-looking

Future strategies and forward-looking



01

Company Brief Introduction

Brief overall

Main Products

DMF/MF Registration Status

Official and Customer Audit Records



Brief overall

● 1982 , Nov. 9 established

- ❑ NT\$ 445,917,130
- ❑ C. M. Hsiao, Chairman
- ❑ 213 employees
- ❑ APIs
- Animal Drugs
- Excipient



● ISO

- ❑ ISO 9001
- ❑ ISO 14001
- ❑ ISO 45001
- ❑ PIC/S GMP
- ❑ GDP
- ❑ ISO 14064-1

● Awards Record

- ❑ National Award in Medicine Quality
- ❑ National Award of Outstanding Research and Development Award in Pharmaceutical Technology
- ❑ National Innovation Award
- ❑ Industrial Sustainable Excellence Award
- ❑ Small and medium enterprise Innovation Award
- ❑ National Innovation Award renewal
- ❑ 2024 Net-Zero Industry Competitiveness Superior Award
- ❑ 2025 Taipei Biotech Awards Go-Global Award - Special Mention Award

● All-round development

- ❑ Manpower cultivation
- ❑ Business fields
- ❑ Infrastructure
- ❑ Cooperate with academic units
- ❑ Develop new drugs with other enterprises



Main Products

SYN-TECH CHEM. & PHARM. CO. LTD.

Product 1

Muscle Relaxants

Product 6

Cardiovascular Agents

Product 2

Central Nervous System Drugs

Product 7

Digestive System Drugs

Product 3

Respiratory System Drugs

Product 8

Chemotherapeutic Drugs

Product 4

Topical Anesthetic Agents

Product 9

**Non- Steroidal Anti- Inflammatory
Antipyretics and Analgesics**

Product 5

Excipient and Animal Drugs

Product 10

Others



DMF/MF Registration Status


SYN-TECH CHEM. & PHARM. CO. LTD.

COUNTRY	DMF/MF (APIs)
U.S.A	18
Japan	22
Canada	3
Korea	5
European Union	6
China	4
Others	9



Official Audit Records

SYN-TECH CHEM. & PHARM. CO. LTD.





Customer Audit Records

SYN-TECH CHEM. & PHARM. CO. LTD.

Audit year	Number / Audit
2020	5
2021	7
2022	11
2023	35
2024	38
Jan.- Oct., 2025	20

A city skyline at sunset with a large downward-pointing triangle containing the number 02. The background features a cityscape with various skyscrapers under a sky with orange and blue clouds. A large, dark grey downward-pointing triangle is centered on the left side, containing the white number '02'. Below this triangle, there are two smaller triangles: a yellow one pointing down and a dark grey one pointing right.

02

Business and Financial Statements


Performance for operation



Revenue of Recent 5 Years

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in million






Product Category Revenue Proportion Between 2025 and 2024 Q3

SYN-TECH CHEM. & PHARM. CO. LTD.


Unit : NT in ten thousand





Sale proportion basis on the Area

SYN-TECH CHEM. & PHARM. CO. LTD.



■ Asia (Except Taiwan and Japan) ■ Japan ■ America ■ Europe ■ Others ■ Taiwan

Data collected form Jan.- Sep., 2025

Revenue Compared Between 2025 and 2024 Q3

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in thousands

Item	Jan.- Sep., 2025	Jan.- Sep., 2024	Differences (%)
Operating revenue	977,296	943,393	4
Gross profit	318,668	356,927	(11)
Gross profit ratio (%)	33	38	(13)
Operating profit	224,226	257,373	(13)
Non- operating income and expenses	(4,950)	120,349	(104)
Profit before tax	219,276	377,722	(42)
Profit after tax	169,729	302,008	(44)
EPS (in dollar)	3.81	6.77	(44)

Sales growth momentum

- The steady growth in performance mainly comes from sales of nervous system and respiratory system medications exported to the Japanese market.
- The increase in intermediate sales volume led to higher revenue.
- New customer development has led to a gradual increase in sales volume.

Operational analysis summary

- Although revenue continued to grow, the overall gross margin declined due to changes in the product mix.
- Impact of exchange rate fluctuations on profit and loss: the appreciation of the NT dollar resulted in currency exchange losses; compared with the same period last year, last year's profit increased due to insurance claim income and currency exchange gains.






EPS and Dividend in Recent 5 Years

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in dollar





03

Strategy in the Future Development & forward-looking

Future strategies and forward-looking



Strategy in the Future Development & forward-looking I

SYN-TECH CHEM. & PHARM. CO. LTD.

● As of the third quarter, AMH sales have reached 2.17 mt; DFP sales have exceeded 1700 kg; and NTP is also actively expanding into the Japanese market.

● Optimization of product manufacturing processes and automation of key steps to provide high-quality products at competitive prices:

- **Process automation enhances efficiency**

CTT, in collaboration with the Development Center for Biotechnology (DCB), is promoting process improvements and has completed a preliminary plan for automating key steps, with an estimated 5% cost reduction.

- **Comprehensive upgrade of plant and equipment**

The reconstruction of plant and facility equipment has been completed. As of the third quarter, combined revenue from the three products CMZ, OPS, and PEH exceeded NT\$32 million.

- **Specialty product R&D continues to contribute**

Although TVP product sales were slightly below expectations, they still generated NT\$18 million in revenue, demonstrating a stable contribution.





Strategy in the Future Development & forward-looking II

SYN-TECH CHEM. & PHARM. CO. LTD.

● Carefully select and evaluate suitable new niche APIs for the future development :

- In line with national policy requirements, strategically valuable products are carefully selected.
- Prioritize the development of essential medicines: for the 481 items on the list of essential drugs, determine the order of importance based on urgency and criticality.
- Prevent domestic drug shortages and ensure a stable supply for the healthcare system.
- Hope for government incentive measures to alleviate financial pressure on the industry.
- Promote a healthy and sustainable development of the industry.



● Expanding New Business Area :

- Assess key intermediates of APIs to strengthen R&D and process capabilities.
- Expand into the China market: advance products such as CTT, AMH, and DFP.
- Continue developing small quantities of specialty APIs PRX to deepen technological differentiation advantages.
- Develop new drugs GFH with other enterprises: licensing has been obtained, development is ongoing, supplying API to Standard, and completing formulation product exports to Japan.



SYN-TECH CHEM. & PHARM.CO.,LTD

Thanks for your attention



生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777